



Back to [Journals](#) > [Stem Cells and Cloning: Advances and Applications](#) > [Volume 15](#) > default

Usage

1 9 4 0

Monthly downloads/views

Average Article Statistics

2 0 Days*

From submission to first editorial decision.

*Business days (Mon-Fri)

Rejection Rate

5 3 %

The above percentage of manuscripts have been rejected in the last 12 months.

Publons | WJCI | ISI CL | SCOPUS

Stem Cells and Cloning: Advances and Applications

Member since 2011
J001215

[Twitter](#) | [Facebook](#) | [LinkedIn](#) | [RSS](#) | [Email](#)

[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | **Articles**

View all (111)	Volume 15, 2022 (6)	Volume 14, 2021 (9)
Volume 13, 2020 (10)	Volume 12, 2019 (5)	Volume 11, 2018 (10)
Volume 10, 2017 (3)	Volume 9, 2016 (2)	Volume 8, 2015 (15)
Volume 7, 2014 (10)	Volume 6, 2013 (3)	Volume 5, 2012 (4)
Volume 4, 2011 (8)	Volume 3, 2010 (19)	Volume 2, 2009 (2)
Volume 1, 2008 (5)		

Search Articles

7 6 6 3 2

Papers Published

[Submit New Manuscript](#)

[Login to view existing manuscript status](#)

[Signup for Journal alerts](#)

About Dove Press

Open access peer-reviewed scientific and medical journals.

[Learn more](#)

Open Access

Dove Medical Press is a member of the OAI.

[Learn more](#)

Reprints

Bulk reprints for the

Archive: Volume 15, 2022

REVIEW

Therapeutic Application of Stem Cells in the Repair of Traumatic Brain Injury

Adugna DG, Aragle H, Kibret AA, Belay DG

[Stem Cells and Cloning: Advances and Applications 2022, 15:53-61](#)

Published Date: **13 July 2022**

ORIGINAL RESEARCH

Rho-Associated Protein Kinase Inhibitor and Hypoxia Synergistically Enhance the Self-Renewal, Survival Rate, and Proliferation of Human Stem Cells

Alsobale S, Alsobale T, Mantalaris S

[Stem Cells and Cloning: Advances and Applications 2022, 15:43-52](#)

Published Date: **2 July 2022**

REVIEW

Prospect of Stem Cells as Promising Therapy for Brachial Plexus Injury: A Systematic Review

Sumarwoto T, Suroto H, Mahyudin F, Utomo DN, Romaniyanto F, Prijosedjati A, Notobroto HB, Tinduh D, Prakoeswa CRS, Rantam FA, Rhatomy S

[Stem Cells and Cloning: Advances and Applications 2022, 15:29-42](#)

Published Date: **22 June 2022**

ORIGINAL RESEARCH

Hypoxia Effects in Intervertebral Disc-Derived Stem Cells and Discus Secretomes: An in vitro Study

Romaniyanto, Mahyudin F, Prakoeswa CRS, Notobroto HB, Tinduh D, Ausrin R, Rantam FA, Suroto H, Utomo DN, Rhatomy S

[Stem Cells and Cloning: Advances and Applications 2022, 15:21-28](#)

Published Date: **27 May 2022**

REVIEW

Therapeutic Application of Stem Cells in the Repair of Traumatic Brain Injury

Adugna DG, Aragie H, Kibret AA, Belay DG

[Stem Cells and Cloning: Advances and Applications 2022](#), 15:53-61

Published Date: **13 July 2022**

ORIGINAL RESEARCH

Rho-Associated Protein Kinase Inhibitor and Hypoxia Synergistically Enhance the Self-Renewal, Survival Rate, and Proliferation of Human Stem Cells

Alsobaie S, Alsobaie T, Mantalaris S

[Stem Cells and Cloning: Advances and Applications 2022](#), 15:43-52

Published Date: **2 July 2022**

REVIEW

Prospect of Stem Cells as Promising Therapy for Brachial Plexus Injury: A Systematic Review

Sumarwoto T, Suroto H, Mahyudin F, Utomo DN, Romaniyanto F, Prijosedjati A, Notobroto HB, Tinduh D, Prakoeswa CRS, Rantam FA, Rhatomy S

[Stem Cells and Cloning: Advances and Applications 2022](#), 15:29-42

Published Date: **22 June 2022**

ORIGINAL RESEARCH

Hypoxia Effects in Intervertebral Disc-Derived Stem Cells and Discus Secretomes: An in vitro Study

Romaniyanto, Mahyudin F, Prakoeswa CRS, Notobroto HB, Tinduh D, Ausrin R, Rantam FA, Suroto H, Utomo DN, Rhatomy S

[Stem Cells and Cloning: Advances and Applications 2022](#), 15:21-28

Published Date: **27 May 2022**

ORIGINAL RESEARCH

Comparative Efficiency for in vitro Transfection of Goat Undifferentiated Spermatogonia Using Lipofectamine Reagents and Electroporation

Nakami WN, Nguhiu-Mwangi J, Kipyegon AN, Ogugo M, Muteti C, Kemp S

[Stem Cells and Cloning: Advances and Applications 2022](#), 15:11-20

Published Date: **10 May 2022**

ORIGINAL RESEARCH

Interleukins Profiling in Umbilical Cord Mesenchymal Stem Cell-Derived Secretome

Chouw A, Sartika CR, Milanda T, Faried A

[Stem Cells and Cloning: Advances and Applications 2022](#), 15:1-9

Published Date: **14 April 2022**

Dr Binetruy

Directeur de Recherche INSERM, Faculte de Medecine, Inserm, France

EDITOR IN CHIEF

Editor-in-Chief: Dr Bernard Binetruy

Dr Bernard Binetruy

Position: Research Director at Inserm (french governmental agency for medical research).

Track record:1980: Master in biochemistry and physiology at the University of Nice.1981-1988: PhD student (1981-1982), then INSERM researcher (1983-1988) at the Centre de Biochimie, Nice (scientific director Dr F. Cuzin). My research was focused on the oncogenic properties of the Bovine Papilloma Virus type1 (BPV1) in rat embryo fibroblasts.

Publications: Nature, EMBO J., Virology, PNAS and Oncogene.

October 1982: Thèse de 3ème cycle and Nov. 1988: Thèse de doctorat d'état in microbiology, University of Nice.

December 1988-June 1991: post-doc fellow in the laboratory of Dr M. Karin, department of pharmacology, School of medicine, UCSD, La Jolla, USA. Fellowship of the Fogarty International Center. During my stay in San Diego I showed that the Ras oncogene augments cJun activity and stimulates phosphorylation of its activation domain and that oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of cJun on serines 63 and 73. This work led to the identification and the characterisation, two years later, by the laboratory of M. Karin of the JNK signal transduction pathway.

Publications: two in Nature (one « full paper ») and two in Mol. Cell. Biol.

June 1991-September 1999: back in France, I started my own lab in Paris area in the Cancer Research Institute, CNRS, Villejuif. We developed a differential screening of a cDNA library to identify and then characterize c-Jun target genes.

Publications: EMBO J., Mol. Cell. Biol., Oncogene and Cell Growth & Diff.

October 1995: Research Director at Inserm.

September 1999-August 2005: I moved to Nice, Inserm U568 laboratory, Faculté de Médecine, Nice. In this new laboratory, I started a new research program focused on the analysis of the molecular mechanisms involved in the differentiation of mouse ES cells.

Publications: Oncogene, Biochem. J., CMLS, Diabetes and Stem Cells.

Since September 2005: I moved to Marseille, Inserm UMR626 laboratory, Faculté de Médecine Timone, Marseille. In this lab, I continue my research on the differentiation of ES cells.

From January 2008: I am the Director of the Institut de Physiopathologie Humaine de Marseille, IFR 125.



Dr Binetruy

Editorial Board

15 Members

Prof. Dr. Blumenfeld ISRAEL

Zeev Blumenfeld, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel

Dr Chaturvedi UNITED STATES



Pankaj Chaturvedi, Dr. Department of Cell and Developmental Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.

Professor Griswold UNITED STATES

Michael Griswold, Professor, School of Molecular Biosciences, College of Sciences, Washington State University, WA, USA

Professor Liebermann UNITED STATES

Dan Liebermann, Professor of The Fels Institute for Cancer Research and Molecular biology; Professor of Medical Genetics & Molecular Biochemistry, Temple Univ. School of Medicine, Philadelphia, PA, USA

Professor Locker UNITED STATES



Joseph Locker, Professor, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Dr Matoso UNITED STATES



Andres Matoso, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

Professor McGuckin FRANCE

Colin P McGuckin, Professor and President, Cell Therapy Research Institute, Lyon, France

Dr Pelus UNITED STATES

Louis M Pelus, Professor, Department of Microbiology and Immunology, Indiana University School of Medicine, IN, USA

Dr Rossi UNITED STATES



John J. Rossi, Lidow Family Research Chair, Professor, Department of Molecular Biology, Dean, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA

Dr Siniscalco ITALY


Dario Siniscalco, ChemD, PhD, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
Dario Siniscalco, Department of Experimental Medicine, School of Medicine and Surgery, Second University of Naples, Italy

Professor Sugaya UNITED STATES



Kiminobu Sugaya, Professor of Medicine and Head of Neuroscience, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, FL, USA

Prof. Dr. Tatullo ITALY



Marco Tatullo, Professor of Applied Technical Medical Sciences University of Bari, Italy. Honorary Senior Lecturer, Dundee University, UK. President of "Stem Cell Biology" Scientific Group, International Association for Dental Research (IADR), UNIBA

Professor Xian AUSTRALIA



Cory Xian, UniSA Clinical & Health Sciences, University of South Australia, Australia

Professor Yarmush UNITED STATES

Martin L. Yarmush, MD, PhD, Paul and Mary Monroe Chair of Science and Engineering and Distinguished Professor of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA

Professor Zaia UNITED STATES



John A. Zaia, M.D., Director, Center for Gene Therapy, Aaron D. and Edith Miller Chair for Gene Therapy; Hematologic Malignancies and Stem Cell Transplantation Institute Department of Hematology, City of Hope, Duarte, CA, USA



UNIVERSITAS AIRLANGGA

FAKULTAS KESEHATAN MASYARAKAT

Kampus C Mulyorejo Surabaya 601115 Telp.031-5920948, 5920949 Fax 031-5924618

Laman : <http://www.fkm.unair.ac.id>; E-mail: info@fkm.unair.ac.id

SURAT KETERANGAN

Nomor : 3148/UN3.1.10/KP/2023

Yang bertandatangan di bawah ini :

Nama : Dr. Santi Martini, dr. M.Kes
NIP : 196609271997022001
Pangkat/Golongan : Pembina / Gol. (IV/a)
Jabatan : Dekan

Dengan ini menerangkan bahwa :

Nama : Dr. Hari Basuki Notobroto, dr., M.Kes
NIP : 196506251992031002
Pangkat/Golongan : Pembina (Gol. IV/a)
Jabatan : Lektor Kepala

Telah melaksanakan penelitian dengan judul sebagai berikut :

No.	Judul Karya Ilmiah	Tahun Pelaksanaan
1	Acute Respiratory Infections Associated with Exposure to Biomass Cooking Fuels and Cigarette Smoke among Children Under Five Years of Age in Developing Countries (C6)	2022
2	Challenges and strategy in treatment with exosomes for cell-free-based tissue engineering in dentistry (C7)	2021
3	Extracellular vesicles: a promising cell-free therapy for cartilage repair (C8)	2019
4	Plant-derived exosome-like nanoparticles: A concise review on its extraction methods, content, bioactivities, and potential as functional food ingredient (C10)	2021
5	Prospect of Stem Cells as Promising Therapy for Brachial Plexus Injury: A Systematic Review (C12)	2022
6	The potential of mesenchymal stem-cell secretome for regeneration of intervertebral disc: A review article (C34)	2021
7	Towards Prevention and Eradication of Leprosy : Current Status and Research Needed in Community Health & Immune Dysregulation (C75)	2020
8	Health risks associated with high waist circumference: A systematic review (C82)	2020
9	Associated Risk of Death From Covid-19 Infection in Patients with Hypertension Co-Morbidities (C120)	2021

Adapun penelitian tersebut layak dilakukan dan menghasilkan output yang sangat baik, meskipun belum ada *Uji Ethical Clearance* karena merupakan penelitian menggunakan metode **Systematic Review**.

Demikian surat keterangan ini kami buat untuk dapat dipergunakan sebagai persyaratan pengusulan Jabatan Fungsional Guru Besar.

Surabaya, 24 April 2023



Dr. Warti Martini, dr. M.Kes
NIP. 196609271997022001

Prospect of Stem Cells as Promising Therapy for Brachial Plexus Injury: A Systematic Review

Tito Sumarwoto^{1,2}, Heri Suroto³, Ferdiansyah Mahyudin³, Dwikora Novembri Utomo³, FNU Romaniyanto², Andhi Prijosedjati², Hari Basuki Notobroto⁴, Damayanti Tinduh⁵, Cita Rosita Sigit Prakoeswa⁶, Fedik Abdul Rantam^{7,8}, Sholahuddin Rhatomy^{9,10}

¹Doctoral Program, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; ²Department of Orthopaedics and Traumatology, Prof Soeharso Orthopaedic Hospital/Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia; ³Department of Orthopaedics and Traumatology, Dr. Soetomo General Hospital/Faculty of Medicine, Airlangga University, Surabaya, Indonesia; ⁴Faculty of Public Health, Airlangga University, Surabaya, Indonesia; ⁵Physical Medicine and Rehabilitation Department, Universitas Airlangga, Surabaya, Indonesia; ⁶Department of Dermatology and Venereology, Dr. Soetomo General Hospital/Faculty of Medicine, Airlangga University, Surabaya, Indonesia; ⁷Virology and Immunology Laboratory, Microbiology Department, Faculty of Veterinary Medicine, Airlangga University, Surabaya, Indonesia; ⁸Stem Cell Research and Development Center, Airlangga University, Surabaya, Indonesia; ⁹Department of Orthopaedics and Traumatology, Dr. Soeradji Tirtonegoro General Hospital, Klaten, Indonesia; ¹⁰Faculty of medicine, public health and nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

Correspondence: Sholahuddin Rhatomy, Department of Orthopaedics and Traumatology, Dr. Soeradji Tirtonegoro General Hospital, Klaten, Indonesia, Email doktergustomrhatomy@yahoo.com

Background: Brachial plexus injury is an advanced and devastating neurological injury, for which both nerve surgery and tendon transfers sometimes remain insufficient in restoring normal movement. Stem cell therapy may be applicable to rescue the injured motor neurons from degeneration which potentially improves muscle strength.

Study Design: Systematic Review; Level of evidence V.

Data Sources: A systematic literature search was conducted on PubMed (MEDLINE), EMBASE, the Cochrane Library, and Scopus using the terms (“stem cell”) AND (“brachial plexus”) as search keywords.

Methods: The process of study selection was summarized by PRISMA flow diagram. The study included in vivo and in vitro studies with English language, humans or animals with some brachial plexus injuries, interventions, some applications of stem cells to the groups of study, with functional, biomechanical, or safety outcomes.

Results: In total, there were 199 studies identified from the literature sources where 75 articles were qualified for forward evaluation following selecting the titles and abstracts. Ten studies were finally included in this systematic review after full-text assessment. Stem cells can produce neurotrophic factors in vitro and in vivo in rats, and their level was increased after injury. Electrophysiological measurement showed that the intervention group had distinctly higher CMAP amplitude and evidently shorter CMAP latency than the model group. Application of bone marrow stem cells (BMSCs) showed an elevation in the numbers of axons and density of myelinated fibers, the density of nerve fibers, the diameter of regenerating axons, and a decrease in axonal degeneration. A study in humans indicated an improvement of the movements in a patient with traumatic total BPI after injection of Ad-MS. It is associated with increased muscle mass and sensory recovery and also suggested that mononuclear cell injection enhances muscle regeneration and reinnervation in the partly denervated muscle of brachial plexus injury. Various muscle groups had obtained strength together with restoration, the muscle strength attained after the previous transplantation were preserved. The results of this review support stem cell treatment in brachial plexus injury.

Conclusion: This review provides evidence of the positive effects of stem cell treatment in brachial plexus injury.

Keywords: stem cell, brachial plexus injury, promising therapy

Introduction

Brachial plexus injury (BPI) is an advanced peripheral nerve injury that results in paralysis of the upper extremities. This injury is often caused by high-energy trauma such as road traffic accidents and young adult groups often experience it. Massive motor neuron damage and impairment functions of the brachial plexus-innervated muscles are the results of severe injury due to the nerve roots avulsion of the brachial plexus.¹⁻³

Various attempts have been performed to save the injured motor neurons from degeneration and to recover the peripheral innervation of muscles, including pharmaceutical administrations and microsurgical interventions during the past decade. However, there is still a limitation regarding the long-term motor neurons survival and the functional outcomes. Massive damage of motor neurons due to injury, presence of extracellular matrix inhibitory molecules such as the chondroitin sulfate proteoglycans (CSPGs), and myelin-associated inhibitors including myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp), Nogo, Netrin-1, and Ephrin in the affected spinal cord and the lack of guidance molecules along the regenerating pathways are related with the poor outcomes in term of functional recovery.⁴⁻⁶

Denervation from injury leads to loss of contractile strength and muscle atrophy. Good restorative ability exists if innervation is restored quickly. In contrast, prolonged interruption of innervation causes irreversible atrophy, fattening of the muscle, and interstitial fibrosis. The muscle could be targeted for cell therapy since the denervated muscle's regeneration depends on its nerve supply as well as its regenerative capability.⁷ Skeletal muscle has a remarkable capability to regenerate mainly due to its resident muscle stem cells (MuSCs). The characteristic of regeneration phase is shown by the activation of the stem cells population known as satellite cells in muscles which replace damaged myofibers.^{8,9}

Recently, strategies for cell replacement have been implemented for treating motor neuron degeneration. Mesenchymal stem cells (MSCs) have become the main interest for neurological repair because of their neural fate and ability to differentiate into neural phenotypes – neural progenitor cells (NPCs). Nevertheless, the environment of injured adult spinal cord does not seem to aid the differentiation of grafted NPCs. Some studies showed evidence that in injured spinal cord, the grafted NPCs will differentiate primarily into glial phenotypes.¹⁰⁻¹³

Grafted NPCs can generate a large quantities of neuron-specific nuclear protein (NeuN)-positive neurons (revealed by all glial fibrillary acidic protein/GFAP positive cells) following transplantation into the ventral horn at 2 weeks after the avulsion. In addition, some of these graft-derived neurons secrete choline acetyltransferase (Ch-AT). These facts indicate that at 2 weeks after the avulsion, the ventral horn supports neuronal differentiation and a conducive environment to generate region-specific neurons.²

The transplantation of NPCs into the ventral horn as a treatment in brachial plexus injury could be a promising therapy, since NPCs have the capacity to differentiate into cell types appropriate to the structure into which they have been grafted. The neurotrophic factors serving to protect the injured neurons also could be secreted.²

As an emerging therapeutic modality, we need a systematic review from current preclinical studies to assign the safety and efficacy. This systematic review is also hoped to provide guidance for the next studies. The major aim of this review is to re-examine the finest obtainable substantiation studies concerning the utilization of stem cells for the management of brachial plexus injuries systematically. We hypothesized that stem cells application will promote brachial plexus regeneration.

Methods

Eligibility Criteria

The inclusion criteria:

- Design of study: in vivo study and in vitro study.
- Group of study: humans or animals with some brachial plexus injuries.
- Interventions: some applications of stem cells to the groups of study.
- Outcomes: either functional, biomechanical, or safety.
- Language: English

Studies in languages other than English, transcriptions, review study and unrelated articles were excluded in this study.

Literature Search and Study Selection

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used as a guideline to perform a comprehensive search of the literature.¹⁴ The search was held in PubMed (MEDLINE), EMBASE, the Cochrane Library, and Scopus. August 2, 2020 was the deadline for all research data used in this study. The terms (“Stem Cell”) AND (“brachial plexus”) were used as search keywords. Two researchers (T.S. and S.R.) separately scanned the titles and abstracts for eligibility after removing duplicates and reviewing the articles. An additional search was done applying the reference lists of the earlier included studies. To apply the inclusion and exclusion criteria, all elected studies were read in full text by the two researchers. A discussion was performed to resolve any disagreement between the two researchers.

Assessment of Methodological Quality and Risk of Bias

Animal Research: Reporting of In vivo Experiments (ARRIVE) guideline was applied to evaluate methodological quality of the included studies.¹⁵ Hence, modified ARRIVE in combination with Consolidating Reporting of Trials (CONSORT) were used.¹⁶ Systematic Review Centre for Laboratory Animal Experimentation’s risk of bias tool (SYRCLE’s RoB tool) was used to assess internal validity.¹⁷ All the assessments were performed by two researchers (T.S. and S.R.) separately. Discussions with other authors were used to resolve any discrepancy.

Extraction and Synthesis of Data

Two researchers (T.S. and S.R.) separately took data from each included study. Some contradictions between the two researchers were addressed by discussion with other researchers. The subsequent data including design of study, type of studies, formation process for humans or animals or cells in the included studies, types of MSCs and their particular donors, the isolation process of the stem cells, interventions, proportion, length of follow-up, the major result for the studies and the outcomes, any significant difference from control or baseline, and other results were extracted.

Any available blinding effort would be notified. The establishment of the humans, animals, interventions and follow-up were also reported. For in vivo studies, any disadvantageous reactions, quantitative outcome measures similar to clinical outcomes and biomechanical tests as the major results were also reported.

Meta-analysis cannot be conducted because of the elevated heterogeneity of the data (i.e. the origin of MSCs, subject, outcome measures, and length of follow-up).

Results

Study Selection

PRISMA flow chart (Figure 1) shows the study selection procedure.¹⁴ There were 199 studies recognized from the literature sources, and 10 studies were finally incorporated for this systematic review.

Study Characteristics

An outline of the study is summarized in Table 1 and certain explanations regarding the study are presented in Table 2 including the types of MSCs and their origins, isolation of the conditioned medium (CM) associated with its subcomponents, models of injury for in vivo study, and the interventions.

Mostly of the studies were performed in China (7 studies/70%), the most common type of study was animal study which accounted for 7 studies (70%), and only 3 studies were conducted in humans. In the animal study literature, 5 studies used rats as models, and 2 studies used rabbits as models. The most common origins of stem cells were from bone marrow (4 studies), spinal cord-derived neural progenitor cells (2 studies), neural stem cells (2 studies), adipose (2 studies), and amnion (1 study).

All of the literature were in vivo studies, but Huanxing Su et al, 2009 performed in vitro and in vivo study in rat.² Five studies used stem cells for the injury of the upper brachial plexus, 2 studies for the lower brachial plexus injury, and 3 studies for total brachial plexus injury.




Figure 1 PRISMA flow chart of study process selection.

Notes: Adapted from: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: <https://doi.org/10.1136/bmj.n71>¹⁴ Creative Commons Attribution (CC BY 4.0) license (<https://creativecommons.org/licenses/by/4.0/legalcode>).

Studies Outcomes

Studies outcomes are summarized in [Table 2](#). This table includes length of follow-up, intervention, and major outcomes measures.

Growth Factor Production

Two studies by Su et al, 2009 and 2011^{2,4} showed that neural progenitor cells (NPCs) can produce brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF). These cells can produce all the substances both in vitro and in vivo. Transplanted NPCs were able to differentiate into choline-acetyltransferase-positive neurons at 2 weeks after the initial injury. BDNF and GDNF were significantly more upregulated in the ventral cord at 2 weeks after injury than those with immediate transplantation or at 6 weeks post injury.

Table 1 Summary of the Included Studies Characteristics

No	Author	Location	Object Study	Study Design
1	Huanxing Su et al, 2009 ⁴	China	Animal Study	In vitro and in vivo
2	M.G. Guo et al, 2020 ¹⁸	China	Animal Study	In vivo
3	Jian-Tao Yang et al, 2019 ¹⁹	China	Animal Study	In vivo study
4	Hua Jin et al, 2015 ²⁰	China	Animal Study	In vivo study
5	Huanxing Su et al, 2011 ²	China	Animal Study	In vivo study
6	Chen Lei et al, 2008 ²¹	China	Animal Study	In vivo study
7	Umang G. Thakkar et al, 2015 ²²	India	Clinical Study (Human)	Case report
8	Hogendoorn et al, 2013 ⁷	Netherland	Clinical Study (Human)	Prospective study
9	Bingqi Wang et al, 2012 ²³	China	Animal Study	In vivo study
10	Alok Sharma et al, 2018 ²⁴	India	Clinical Study (Human)	Case report

A study conducted by Wang et al, 2012 described that neural stem cells produced neurotrophic factors following root avulsion injury of brachial plexus. These three neurotrophic factors are BDNF, NGF, and NT-3, and their level was increased after injury.²³

Electrophysiological Measurement

A study by Guo et al, indicated that the intervention group had distinctly higher CMAP amplitude and shorter CMAP latency than the model group.¹⁸ Lei et al conducted an anterior approach assessment of the latency and compound muscle action potential (CMAP) of left musculocutaneous nerve after neurotrophin-3 (NT-3) gene transfer into NSCs with the help of the pLEGFP-C1 (vector of expression plasmid) at the 12th month. The stimulator was attached to the nerve and acceptor to muscle belly of biceps. The results of this examination indicated that the result in the pLEGFP-C1-NT-3 group was excellent in comparison to the pLEGFP-C1 group or NSCs untransfected group.²¹ The other study stated an increase in action potential of compound muscle and motor conduction velocity.¹⁹

Histological Changes of Impaired Nerve Tissue Sections

BMSCs-treated BPI showed an increase in numbers of axons and myelinated fibers, the nerve fibers density, and the numbers of axonal regeneration, and a decrease in axonal degeneration;¹⁸ another study by Yang et al showed a remarkable increase in regenerating the axon's diameter, myelin sheath's thickness, and myelinated fibers' density.¹⁹

Differentiation of Adult and Neonatal Endogenous Neural Stem Cells in Secreting Neurotrophic Factors

Wang et al 2012 described that the levels of BDNF, NGF, and NT-3 increased following root avulsion injury of brachial plexus. One day after injury the levels of BDNF, NGF, and NT-3 escalated rapidly in adult rats which then slowly reduced to normal levels within 21 days as shown by real-time PCR. In contrast, in neonatal rats, the levels of these neurotrophic factors diminished on the first day following injury. The levels then escalated slowly starting the 7th day and permanently at high levels for a certain time period.²³

Human Study Outcome

A case report by Thakkar et al indicated that an improvement of finger movements was observed in a patient with traumatic total BPI after injection of Ad-MS. Gradually finger movements of the patient developed and they were associated with an increase in muscle mass and improvement of sensory function. There was improvement in muscle

Table 2 Outcomes Measures Summaries

No	Author	Type - Source of Stem Cells	Subject	Follow-Up	Location Injury	Intervention	Outcome
1	Huanxing Su et al, 2009 ⁴	Rat – Spinal cord-derived (NPCs)	Rat	6 weeks	Avulsed C7-C8 ventral horn	Grafting of spinal cord-derived NPCs to the acutely avulsed adult rats' ventral horn	NPCs produced NGF, BDNF, and GDNF in vitro and in vivo. NPCs exert benefit for the viability and regeneration of avulsed-injured axonal motor neurons following grafting
2	M.G. Guo et al, 2020	Bone Marrow, rabbit	Rabbit	3 weeks	C5-T1 brachial plexus root avulsion	BMSCs were transfected with RFP to construct RFP-BMSCs. The RFP-BMSCs (5×10^6 , the treat group) and normal saline (the model group) injected intraperitoneally. Following measurement: recovery rate of the upper limb muscle wet weight, done by weighing	Intervention group exhibited a notably increased wet muscle weight recovery rate in comparison with the model group. Electrophysiological measurement of the CMAP in the intervention group had distinctly higher CMAP amplitude and evidently shorter CMAP latency than the model group ($p < 0.05$). RFP-BMSCs were visibly arranged on both sides of nerve fibers in the intervention group (under fluorescence microscope). Comparison p-MAPK and p-ERK expressions in the treatment group with model group was significantly different ($p < 0.05$)
3	Umang G. Thakkar et al, 2015	Autologous N-AD-MSC and HSC-BM	Humans	3 years	Post-traumatic brachial plexus injury C5-T1	Generating Ad-MSCs from 10 g abdominal fat and HSCs from 100 mL bone marrow, trypsinization and verifying for viability and sterility, the harvested MSCs were differentiated into NSCs by a self-designed neural differentiation medium, following 4 days of isolation by concentration gradient separation medium. The above inoculum was mixed with HSCs which was generated on day 10. Never used xenogeneic material. Stem cells inoculum 2.8 mL in total administered on day 14 using local anesthesia in the right brachial plexus sheath by brachial block technique under USG guidance	Finger movements gradually developed associated with an elevating muscle mass and sensory restoration. Increasing finger muscle strength (grade 0 to grade 2 based on Kendall and McCreary manual muscle testing) after 1 year. Replicate EMG-NCV expressed reinnervation in musculocutaneous, radial, axillary, and suprascapular nerve and few motor unit potentials responsible in recruiting the biceps, triceps, deltoid, and infraspinatus muscles. All functions maintained for the last 3 years

4	Jian-Tao Yang et al, 2019	Adipose stem cells, Rat	Rat	16 weeks	Upper brachial plexus injury	<p>Three groups divided randomly rats: acellular nerve allograft, acellular nerve allograft + differentiated adipose stem cells, and autograft.</p> <p>Micro-hemostat forceps was used for traction away from the intervertebral foramen to establish the upper brachial plexus injury model.</p> <p>Acellular nerve allografts with or without seeded cells were used to bridge the gap between the contralateral C7 nerve root and C5-C6 nerve</p>	<p>Functional recovery sequence: 1. autograft group; 2. acellular nerve allograft + differentiated adipose stem cells group; 3. acellular nerve allograft group.</p> <p>Significant difference in term of recovery between autograft and acellular nerve allograft groups, comparing the acellular nerve with allograft group, compound muscle action potential, motor conduction velocity, the diameter of regenerating axons, positivity for neurofilament and S100, myelin sheath thickness, and density of myelinated fibers were remarkably increased in autograft.</p> <p>In the acellular nerve allograft with differentiated adipose stem cells group gives an insight that acellular nerve allograft + differentiated adipose stem cells effectively started the recovery of the nerve after brachial plexus injuries, and the result was better than that of acellular nerve recovery alone</p>
5	Hua Jin, 2015	Human amniotic epithelial cells	Rabbit	26 weeks	The C6 root avulsion method was used for the rabbit model of brachial plexus injury	<p>Repeated injection of human amniotic epithelial cells suspension at the area 4.0 mm lateral to the cephalic and caudal ends of the C6 brachial plexus injury site (1×10^6 cells/mL, 3 μL/injection, 25 injections) soon following the injury</p>	<p>The stress reduction and strain increase at 7200 seconds in the injured rabbit C6 brachial plexus were lessened by the cell grafting, recovering the viscoelastic stress relaxation and creep properties of the brachial plexus. The forepaw functions were significantly improved at 26 weeks following injury.</p> <p>Human amniotic epithelial cells grafting may efficaciously recover the mechanical properties of the injured brachial plexus in rabbits, and viscoelasticity could be an important index for brachial plexus injury recovery evaluation in animals</p>

(Continued)

Table 2 (Continued).

No	Author	Type - Source of Stem Cells	Subject	Follow-Up	Location Injury	Intervention	Outcome
6	Hogendoorn et al, 2013	Autologous bone marrow-derived mononuclear cell	Humans	Three and six months	Nine patients of brachial plexus injury with elbow flexion insufficient (C5-C6)	Insufficient elbow flexion in 9 brachial plexus injury patients (i.e., partial denervation) admitted intramuscular of autologous bone marrow-derived mononuclear cells, in combination tendon transfers	<p>Histological examination revealed</p> <ul style="list-style-type: none"> - 52% muscle fibrosis declining (p = 0.01) - 80% myofiber diameter elevating (p = 0.007) - 83% capillary-to-myofiber ratio elevating (p < 0.001) - 50% satellite cells count elevating (p = 0.045) <p>CT analysis demonstrated:</p> <ul style="list-style-type: none"> - 48% mean muscle density declining (p = 0.009) <p>Motor unit analysis:</p> <ul style="list-style-type: none"> - 36% mean elevating in motor unit amplitude (p = 0.045) - 29% number of phase elevating (p = 0.002) - 22% duration elevating (p = 0.005)
7	Huanxing Su et al, 2011	Spinal cord-derived neural progenitor cells, Rat	Rat	2 and 6 weeks	C7 root avulsion of brachial plexus	Grafted spinal cord-derived NPCs into the adult rats' cervical ventral horn shortly, 2 weeks, or 6 weeks following root avulsion to assign an optimal time scale for the viability and differentiation of grafted cells	<p>Grafted NPCs remained alive greatly at all three time points. Two weeks post avulsion grafting significantly increase neuronal differentiation of grafted NPCs compared with shortly grafting or at 6 weeks post avulsion. Two weeks after NPCs grafting, the stem cells can differentiate into ChAT-positive neurons.</p> <p>BDNF and GDNF were remarkably upregulated in the ventral cord, more prominently observed at 2 weeks post avulsion than shortly or at 6 weeks post avulsion</p>

8	Chen Lei et al, 2008	Rat neural stem cells	Rat	12 months	Brachial plexus C5-C7 root avulsion	<p>Extracted RNA from the neonatal rat striatum and the NT-3 cDNA by reverse transcription.</p> <p>The NT-3 gene was transferred into NSCs via the pLEGFP-C1 (an expression plasmid vector). The untransfected NSCs, the pLEGFP-C1 treated NSCs, and the pLEGFP-C1-NT-3 treated NSCs were grafted into the corresponding spinal cord segment with brachial plexus root avulsion.</p> <p>The viability, differentiation, and migration of the grafted cells were determined under a confocal laser scanning microscope or by immunohistochemistry method. Gross observation, electrophysiological examination and reverse horseradish peroxidase tracing were used to evaluate the nerve regeneration</p>	<p>The NT-3 gene was effectively magnified and transferred into neural stem cells with the help of the plasmid vectors.</p> <p>The grafted cells eventually remained alive, differentiated, migrated, and finally NT-3 was demonstrated within the spinal cord.</p> <p>The animals recovered some muscle power less than 3-degree muscular power based on the BMRC evaluating system. The pLEGFP-C1 - NT-3 group had an excellent outcome regarding the electrophysiological examination and reverse horseradish peroxidase tracing compared with the NSCs untransfected group or the pLEGFP-C1 group</p>
9	Bingqi Wang et al, 2012	Rat neural stem cells	Rat	Thirty-five days	Brachial plexus C5 - C6 root avulsion	<p>R-T PCR assessing to gene expression of BDNF, NGF, NT-3 in the spinal cord following brachial plexus root avulsion injury at adult and neonatal rats, immunohistochemical staining for observing the proliferation and differentiation of endogenous neural stem cells, to assign if neonatal rats have a higher rate of differentiation of endogenous neural stem cells into neurons and higher neurotrophin expression compared with adult rats following brachial plexus root avulsion injury</p>	<p>Expression of BDNF, NGF, NT-3 were significantly higher in neonatal than in adult rats. Before brachial plexus injury, the expression of those neurotrophic factors was remarkably higher in neonatal rat and after brachial plexus root avulsion injury the expression was remarkably increased in adults. The highest expression level was at the 7th day and regularly declined to degree before injury at 21st day.</p> <p>BDNF gene expression regularly regained after the first 7 days, peak degree at 21 days.</p> <p>NGF gene expression was at its lowest at 7 days following injury, start to elevate after 14 days, and peaked at 21 days.</p> <p>NT-3 gene expression elevated on the 7th day following injury and peaked on the 21st day.</p> <p>BrdU/nesin-positive cells elevate in adult rats from the 1st day following injury, peaked by 14 days, and regularly declined.</p> <p>BrdU/nesin-positive cells elevate starting on the 1st day following injury in neonatal rats, peak on the 7th day.</p> <p>Cells are particularly detected near the ependyma and the gray matter in neonatal rats. The amount of positive cells was larger in adult than in neonatal rats at the identical time point.</p> <p>BrdU/GFAP-positive cells elevate in adult and neonatal rats starting at the 14th day following injury and peaked on the 35th day, particularly found near the central canal and spinal cord gray matter. The amount of positive cells remarkably elevated in adult and neonatal rats at 14 and 35 days following injury.</p> <p>The amount of BrdU/GFAP-positive cells in adult rats was remarkably greater than in neonatal rats. BrdU/β-tubulin-positive cells were not detected</p>

(Continued)

Table 2 (Continued).

No	Author	Type - Source of Stem Cells	Subject	Follow-Up	Location Injury	Intervention	Outcome
10	Alok Sharma et al, 2018	Autologous bone marrow mononuclear stem cells (BMMNCs)	Humans	4 years	Post-traumatic brachial plexus injury C5-T1	<p>BMMNCs were injected intrathecally L4-L5 and 19 specific motor point affected sides intramuscularly, simultaneous intravenous 1 g methylprednisolone in 500 mL RL. Total number of injected cells was 219×10^6 with 94% viability.</p> <p>Multidisciplinary neurorehabilitation, occupational therapy, and theraband exercises with the assist of normal arm twice in a day, psychologist counseling, routine blood (pre-post the intervention).</p> <p>Discharged at 1-week post-transplantation, exhorted to continue the rehabilitation at home. Perform evaluation 3 and 7 months post-therapy. The patient underwent second cells transplantation 8 months following the first transplantation with the repeated approach.</p>	<p>One week post-transplantation: restoration in abduction-adduction right shoulder, felt contraction of the biceps-triceps.</p> <p>Three months transplantation: improved shoulder pushing movement, evident potent biceps, deltoid, pectoralis, and subscapularis contraction. Felt tingling and numbness sensation entire the right extremity at rest and elevated with the strength of motion. Reduce shoulder joint subluxation. ROM improved by 15–20° while doing the suspension exercises. Diminish atrophy of pectoral, thenar and hypothenar muscles. EMG exams: extended latency and very little amplitude in right axillary, musculocutaneous and radial triceps muscles in progress action of reinnervation right infraspinatus and biceps muscles, with FIM score 125.</p> <p>Seven months transplantation: flicker contraction pectoralis major, middle deltoid, teres major, and sustained the deltoid fibers before. Positive tincl sign associate paresthesia entire the nerve recovery in regeneration, a shift of 3.5 inches distally in the degree of tincl sign under the humeral head that was obvious in the beginning at the humeral head, delayed response of little amplitude was detected in musculocutaneous biceps and axillary deltoid muscles repeating the EMG suggesting the process of reinnervation. No reaction was noticed in the EMG inventions in those muscle before the cellular treatment.</p> <p>Alterations were detected following the first cell transplantation. Second transplantation within one week, reduced finger swelling, a shift tincl sign 2 inches down the forearm, further repaired biceps muscles contraction, felt sensation up to the elbows, completely paused muscles atrophy in the right forearm and palm, the muscles had repaired. Following 3 months of the second cell transplantation indicated developments in the static contractions of the biceps, improvement in flexion of the wrist, improvement in palmaris longus tendon function, vague contraction of long flexor middle finger. Followed up after 4 years: ROM had increased and good hand function, other restorations were maintained and no impairment in muscles power over 4 years. Several muscle groups had obtained power and restorations in the muscle power gained following the prior transplantation were preserved.</p>

power of the finger from grade 0 to grade 2 after 1 year based on Kendall and McCreary manual muscle testing. A replicate EMG-NCV examination indicated reinnervation in some nerves including musculocutaneous, radial, axillary, and suprascapular nerves. It also revealed several motor unit potentials were recruited in biceps, triceps, deltoid, and infraspinatus muscles, which has been preserved for the last 3 years.²²

A study by Hogendoorn et al on nine patients revealed reduction of muscle fibrosis by 52% ($p = 0.01$), an 80% elevating of myofiber diameter, elevating satellite cell count by 50%, and elevating in capillary to myofiber ratio by 83%. CT analysis revealed a 48% reduction in mean muscle density (MMD). The analysis of motor unit demonstrated an average elevation of 36% in amplitude of motor unit. In this case, there was a 22% elevation in duration and 29% elevation in the number of phases. This study suggests that mononuclear cell injection enhances muscle regeneration and reinnervation in incomplete denervated muscles of the injured brachial plexus.⁷

Sharma et al reported a case with brachial plexus injury due to a road traffic accident (RTA). The follow up was done after four years from the first cell transplantation. The upper extremity range of motion had increased and there was a good function of the hand. The other restorations were maintained and there was no decline in muscle power over 4 years. Several muscle groups had obtained power and restorations in the muscle power attained following the previous transplantation were preserved.²⁴

Discussion

The goal of nerve surgery in brachial plexus injuries is to restore innervation of the muscle, and in the elbow, it is flexion of the biceps muscle, even though there might be a deficit in arm function. In this case, secondary surgery is needed to improve arm function. This improvement is related to the transfer of the forearm flexor-pronator group (Steindler procedure) for the flexion of the elbow actively. Nevertheless, neurosurgery or tendon transfer cannot restore normal elbow flexion.^{7,25}

Stem cells transplantation will become an efficacious treatment for many neurological disorders and injuries. Stem cells or progenitor cells treatment which had been shown by numerous animal studies can save some level of neurological function following the injury. A lot of positive outcomes following cells therapy seem to be related to salvage of the existing tissue rather than the repair or replacement of damaged tissue. The transplanted cells release growth factors, cytokines, and hormones to provide most of the benefits. These proteins have paracrine effect following the transplantation of the stem cells/progenitor cells. These include neuroprotection, trophic support, guidance for axonal outgrowth, and glial scar control.^{10,26}

A narrow time window was provided for efficacious strategies of cell engrafting that have been previously demonstrated by some reports regarding the management of spinal cord injury. Severe acute inflammation is proven to occur immediately after spinal cord transection injury. Numerous cytokines for inflammation with the impacts of leading astrocyte or neurotoxicity are produced post-transection. The levels of Interleukin-1, Interleukin-6, and Tumor Necrosis Factor- α are very expressive in the beginning but then reduce sharply within 24 hours. During acute phase at the spinal cord injury, the microenvironment is unsavory for grafted cells neuronal differentiation due to acute inflammatory response. The glial scars development, the inhibitory molecules presentation, and the trophic factors lacking are the conditions that make therapeutic transplantation ineligible at the chronic phase of spinal cord injury. NPCs subacute transplantation at two weeks post-injury leads to a major viability and differentiation of engrafted cells and promotes useful restoration as well. Meanwhile, the grafted cells in transplantation models at 6–8 weeks post-injury (chronic) after spinal cord injury remain alive unsatisfactorily and show no impact on the useful restoration.²

The ideal origins of stem cells for clinical therapy must have these following characteristics, including the ability of the stem cells to be personalized, no immune rejection and tumorigenesis, simple to obtain and amplify, and efficacious in cellular or molecular replacement. The potent cell resources for grafting are mesenchymal stem cells (MSCs) and neural stem cells that may be extended in a long period of time.^{26,27}

The ventral horn NPCs transplantation would be giving a good result for managing brachial plexus injury due to its differentiation capacity. NPCs are able to differentiate to the same cell type where they have been grafted. Following grafting into the ventral horn, human neural NPC-derived motor neurons can create axonal growth via the ventral root

and peripheral nerve to establish neuromuscular junctions with their muscle targets, raising the possibility of cell replacement therapy for motor neurons loss.^{2,13}

NPCs can secrete several neurotrophic factors both *in vitro* and *in vivo* for protecting injured neurons. These neurotrophic factors are brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF).^{2,4} These growth factors are potent factors for neuronal survival and axonal growth.² One of the primary contributing factors to the poor functional recovery following peripheral nerve injury is the progressive decline in the capacity of motor neurons to regenerate their axons. This particularly happens over a long period in which the motor neurons remain axotomized before reinnervating the denervated muscle target.²⁸ Therefore, the application of small doses of neurotrophic factors such as GDNF and BDNF can improve the poor functional recovery of peripheral nerve injury due to trauma by promoting the regeneration of axons in the chronically axotomized motor neurons. The presence of these neurotrophic factors encourages regeneration, increases the axonal myelination level, and augments the recovery of the sensory and motor function.^{29,30}

The survival of injured motor neurons and their regeneration were significantly enhanced by transplanted NPCs in the avulsed ventral horn. These facts suggest that NPCs have beneficial effects on the avulsed motor neurons' survival and axonal regeneration. This beneficial effect may be due to their innate ability to release some trophic factors *in vivo*.⁴ The stem cells transplantation by implantation of MSCs locally in the injured peripheral nerve has proven to promote the regeneration of nerve by axonal regrowth and formation of myelin. Mesenchymal stem cells apparently act as the neurotrophic generator which encourages functional recovery through neurogenesis, synaptogenesis, angiogenesis, and axonal remodeling.²²

Stem cells promoted brachial plexus regeneration in preclinical studies. Ten *in vivo* studies have shown promising results in the majority of cases. These interventions were sustained by *in vitro* and *in vivo* studies, in which growth factor production was increased. Additionally, according to human studies, it was shown that there were improvements in motor and sensory recovery,^{7,22} and the muscle biopsy showed a decrease in the amount of muscle fibrosis and an elevation in the diameter of myofiber, satellite cells, and the ratio of capillary-to-myofiber.⁷ Side effects concerning the utilization of stem cells were not reported in these studies.

Schwann cells as the orchestrators of the peripheral nerve restoration will proliferate and arrange the myelin sheath to encourage the renovation of axon starting from the proximal to the distal end. According to these studies, stem cells can enhance the conduction velocity of CMAP and thicken the myelin sheath.^{18,20} These features supported the hypothesis that electrical stimulation (ES) encourages the proliferation and myelination of Schwann cells.^{31,32} The feature of compound muscle action potential (CMAP) at EMG is an important index to assess neuromuscular recovery, serving as the earliest EMG measurement for the recovery of muscular function.³¹

Besides the regeneration of the nerve, it is also important to achieve muscle restoration and reinnervation of partially denervated muscle in brachial plexus injury. Stem cell therapy has the ability to potentially repair muscle strength.³³ The application of autologous BM-derived mononuclear cells (MNCs) has been done in muscle-focused clinical studies of the heart and leg. Injection of autologous BM-derived MNC in a partially denervated biceps muscle is secure, with no adverse effects regarding vital signs, bone marrow aspiration sites, injection sites, or surgical wounds. Mild anemia was found but fully recovered. The interstitial fibrosis which usually occurs in the long term was diminished by 52% after MNCs injection. These results were in accordance with the pictures of CT scan analysis that illustrated a reduction of 48% in mean muscle density/MMD.⁷

This study has several limitations. First, the *in vivo* studies need more human subjects so that the effect of mesenchymal stem cells in the peripheral nerve regeneration after brachial plexus injury in humans can be assessed further; second, the *in vivo* study in humans did not mention the severity of the peripheral nerve injury to brachial plexus so we could not determine whether stem cells can promote and regenerate the peripheral nerve tissue in all classifications of peripheral nerve injury; third, this study has high heterogeneity of data such as the origin of MSCs, subjects, outcomes, and follow-up duration; fourth, only English language journals were included in this review which may lead to a potential bias; and lastly the side effects regarding the injection of the stem cells in brachial plexus injury were not reported in these studies.

Conclusion

Utilization of stem cells in brachial plexus injuries holds promise in enhancing the healing process, regeneration of the nerve and the denervated muscles, as demonstrated by the available preclinical (in vitro and in vivo) and clinical studies. However, more preclinical and clinical studies are required to further assure the advantages and to determine the most appropriate stem cells to be used in injury cases.

Abbreviations

Ad-MSCs, Adipose-derived Mesenchymal Stem Cells; BDNF, Brain-derived Neurotrophic Factor; BM, Bone Marrow; BMRC, British Medical Research Council; BMSCs, Bone Marrow Stem Cells; BPI, Brachial Plexus Injury; CD, Cluster of Differentiation; Ch-AT, Choline Acetyl Transferase; CM, Conditioned Medium; CMAP, Compound Muscle Action Potential; CT, Computed Tomography; EMG, Electromyography; ES, Electrical Stimulation; pERK, phosphorylated Extracellular signal Regulated Kinase; GDNF, Glial Cell-derived Neurotrophic Factor; GFAP, Glial Fibrillary Acidic Protein; HSCs, Hematopoietic Stem Cells; HSC-BM, Bone Marrow derived Hematopoietic Stem Cells; IL, Interleukin; pMAPK, phosphorylated Mitogen-Activated Protein Kinase; MMD, Mean Muscle Density; MNCs, Mononuclear Cells; MSCs, Mesenchymal Stem Cells; Neu N, Neuron-specific nuclear protein; N-AD-MSC, Neuronal differentiated-Adipose tissue-derived-Mesenchymal Stem Cells; NCV, Nerve Conduction Velocity; NPCs, Neural Progenitor Cells; NGF, Nerve Growth Factor; NT-3, Neurotrophin-3 gene; NSCs, Neural Stem Cells; PCR, Polymerase Chain Reaction; RFP, Red Fluorescent Protein; ROM, Range of Movement; RTA, Road Traffic Accident; TNF- α , Tumor Necrosis Factor- α ; USG, Ultrasonography.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Yoshikawa T, Naoto Hayashi S, Yamamoto YT, et al. Brachial plexus injury: clinical manifestations, conventional imaging findings, and the latest imaging techniques. *RadioGraphics*. 2006;26:133–144. doi:10.1148/rg.26si065511
2. Su H, Wu Y, Yuan Q, Guo J, Zhang W, Wu W. Optimal time point for neuronal generation of transplanted neural progenitor cells in injured spinal cord following root avulsion. *Cell Transplant*. 2011;20(852):167–176. doi:10.3727/096368910X522090
3. Tu Y-K, Tsai Y-J, Chang C-H, Su F-C, Hsiao C-K, Tan JS. Surgical treatment for total root avulsion type brachial plexus injuries by neurotization: a prospective comparison study between total and hemicontralateral C7 nerve root transfer. *Microsurgery*. 2013;34(2):91–101. doi:10.1002/micr.22148
4. Su H, Zhang W, Guo J, Guo A, Yuan Q, Wu W. Neural progenitor cells enhance the survival and axonal regeneration of injured motoneurons after transplantation into the avulsed ventral horn of adult rats. *J Neurotrauma*. 2009;80:(January):67–80. doi:10.1089/neu.2008.0656
5. Mekaj A, Mekaj Y. The role of pharmacological agents in nerve regeneration after peripheral nerve repair. *Peripher Nerve Regen Surg New Ther Approaches Incl Biomater Cell Based Ther Dev*. 2017;2017:147–174.
6. Van Niekerk EA, Tuszynski MH, Lu P, Dulin JN. Molecular and cellular mechanisms of axonal regeneration after spinal cord injury. *Mol Cell Proteom*. 2016;15(2):394–408. doi:10.1074/mcp.R115.053751
7. Hogendoorn S, Duijnisveld BJ, Van Duinen SG, et al. Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury: a pilot study. *Bone Joint Res*. 2014;3(2):38–47. doi:10.1302/2046-3758.32.2000229
8. Musarò A. The Basis of Muscle Regeneration. *Adv Biol*. 2014;2014:1–16. doi:10.1155/2014/612471
9. Relaix F, Benzeq M, Borok MJ, et al. Perspectives on skeletal muscle stem cells. *Nat Commun*. 2021;12(1):1–11. doi:10.1038/s41467-020-20760-6
10. Nutt SE, Chang E-A, Suhr ST, et al. Caudalized human iPSC-derived neural progenitor cells produce neurons and glia but fail to restore function in an early chronic spinal cord injury model. *Exp Neurol*. 2013;248:491–503. doi:10.1016/j.expneurol.2013.07.010
11. Ke Y, Chi L, Xu R, Luo C, Liu R, Liu R. Early response of endogenous adult neural progenitor cells to acute spinal cord injury in mice. *Stem Cells*. 2006;24(4):1–17. doi:10.1634/stemcells.2005-0249
12. Park KI, Ourednik J, Ourednik V, et al. Global gene and cell replacement strategies via stem cells. *Gene Ther*. 2002;9(10):613–624. doi:10.1038/sj.gt.3301721
13. Dulin JN, Adler AF, Kumamaru H, et al. Injured adult motor and sensory axons regenerate into appropriate organotypic domains of neural progenitor grafts. *Nat Commun*. 2018;9(1):1–13. doi:10.1038/s41467-017-02613-x
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
15. Kilkeny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. *Br J Pharmacol*. 2010;160(7):1577–1579. doi:10.1111/j.1476-5381.2010.00872.x
16. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Br Med J*. 2010;10:1–28.

17. Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol.* 2014;14(1):1–9. doi:10.1186/1471-2288-14-43
18. Guo M, Li D, Wu L, Li M, Yang B. Bone marrow mesenchymal stem cells repair brachial plexus injury in rabbits through ERK pathway. *Eur Rev Med Pharmacol Sci.* 2020;24:1515–1523. doi:10.26355/eurrev_202002_20210
19. Yang J, Fang J, Li L, Chen G, Qin B, Gu L. Contralateral C7 transfer combined with acellular nerve allografts seeded with differentiated adipose stem cells for repairing upper brachial plexus injury in rats. *Neural Regen Res.* 2019;14(11):1932–1940. doi:10.4103/1673-5374.259626
20. Jin H, Yang Q, Ji F, Zhang Y, Zhao Y, Luo M. Human amniotic epithelial cell transplantation for the repair of injured brachial plexus nerve: evaluation of nerve viscoelastic properties. *Neural Regen Res.* 2015;10(2):260–265. doi:10.4103/1673-5374.152380
21. Lei C, Lai-jin LU, Xiao-ting M, Dong C, Zhi-xin Z, Fan Y. Reimplantation combined with transplantation of transgenic neural stem cells for treatment of brachial plexus root avulsion. *Chin J Traumatol.* 2008;11(5):267–273. doi:10.1016/S1008-1275(08)60054-1
22. Thakkar UG, Aruna V, Vanikar HLT. Co-infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and bone marrow derived hematopoietic stem cells, a viable therapy for post-traumatic brachial plexus injury: a case report. *Biomed J.* 2014;37(4):237–240. doi:10.4103/2319-4170.132893
23. Wang BQ, Chen L, Liu B, et al. Differentiation of endogenous neural stem cells in adult versus neonatal rats after brachial plexus root avulsion injury. *Neural Regen Res.* 2012;7(23):1786–1790. doi:10.3969/j.issn.1673-5374.2012.23.004
24. Sharma A, Sane H, Gokulchandran N, et al. Cellular therapy for chronic traumatic brachial plexus injury. *Adv Biomed Res.* 2018;7(1):51. doi:10.4103/2277-9175.228631
25. Fox IK, Miller AK, Curtin CM. Nerve and tendon transfer surgery in cervical spinal cord injury: individualized choices to optimize function. *Top Spinal Cord Inj Rehabil.* 2018;24(3):275–287. doi:10.1310/sci2403-275
26. Hsu YC, Chen SL, Wang DY, Chiu IM. Stem cell-based therapy in neural repair. *Biomed J.* 2013;36(3):98–105. doi:10.4103/2319-4170.113226
27. Ottoboni L, Merlini A, Martino G. Neural stem cell plasticity: advantages in therapy for the injured central nervous system. *Front Cell Dev Biol.* 2017;5:1–21. doi:10.3389/fcell.2017.00001
28. Boyd JG, Gordon T. Glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor sustain the axonal regeneration of chronically axotomized motoneurons in vivo. *Exp Neurol.* 2003;183(2):610–619. doi:10.1016/S0014-4886(03)00183-3
29. Wang C, Lu CF, Peng J, Hu CD, Wang Y. Roles of neural stem cells in the repair of peripheral nerve injury. *Neural Regen Res.* 2017;12(12):2106–2112. doi:10.4103/1673-5374.221171
30. Houlton J, Abumaria N, Hinkley SFR, Clarkson AN. Therapeutic potential of neurotrophins for repair after brain injury: a helping hand from biomaterials. *Front Genet.* 2019;10:1–23. doi:10.3389/fgene.2019.00001
31. Zhang XU, Xin NA, Tong LEI, Tong X. Electrical stimulation enhances peripheral nerve regeneration after crush injury in rats. *Mol Med Rep.* 2013;7(2013):1523–1527. doi:10.3892/mmr.2013.1395
32. Choi EH, Blasiak A, Lee J, Yang IH. Modulation of neural activity for myelination in the central nervous system. *Front Neurosci.* 2019;13:1–6. doi:10.3389/fnins.2019.00952
33. Judson RN, Rossi FMV. Towards stem cell therapies for skeletal muscle repair. *NPJ Regen Med.* 2020;5(1):1–6. doi:10.1038/s41536-020-0094-3

Stem Cells and Cloning: Advances and Applications

Dovepress

Publish your work in this journal

Stem Cells and Cloning: Advances and Applications is an international, peer-reviewed, open access journal. Areas of interest in established and emerging concepts in stem cell research include: Embryonic cell stems; Adult stem cells; Blastocysts; Cord blood stem cells; Stem cell transformation and culture; Therapeutic cloning; Umbilical cord blood and bone marrow cells; Laboratory, animal and human therapeutic studies; Philosophical and ethical issues related to stem cell research. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/stem-cells-and-cloning-advances-and-applications-journal>